PCR Firm QuantaLife Raises $17.2M in Series B | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PCR technology development company QuantaLife announced late Friday that it had closed on a Series B financing round, raising $17.2 million.

The majority of the funds will be used to create a commercialization operation to launch its Droplet Digital PCR platform for the research market and to accelerate development of targeted diagnostic tests, the Pleasanton, Calif.-based company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.